"CureVac’s COVID-19 Vaccine Data Encouraging: CureVac N.V. (CVAC Quick QuoteCVAC - Research Report) announced that its phase IIb/III study on COVID-19 vaccine candidate, CVnCoV, will continue following the first interim analysis in 59 eligible COVID-19 cases.
The independent Data Safety Monitoring Board (DSMB) confirmed that the phase IIb/III study (HERALD) for CVnCoV has passed the first interim analysis in 59 adjudicated COVID-19 cases with no safety concerns. Consequently, the trial will continue to collect sufficient data in order to conduct a statistically significant efficacy analysis.
The HERALD study has enrolled approximately 40,000 participants in ten countries in Latin America and Europe. ..."